Compatibility of calcipotriene with other topical medications

Patel, Bhiku; Siskin, Stewart B.; Krazmien, Rick; Lebwohl, Mark

doi:10.1016/s0190-9622(98)70171-9

Cited by 91 publications

(32 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It would clearly be advantageous to have calcipotriol and a corticosteroid combined in the same treatment, to avoid the need for separate applications of each. Also, when applied separately interactions cannot be excluded – for example, calcipotriol can be unstable when mixed with other topical preparations [11]. …”

Section: Introductionmentioning

confidence: 99%

A New Calcipotriol/Betamethasone Dipropionate Formulation (Daivobet<sup>TM</sup>) Is an Effective Once-Daily Treatment for Psoriasis vulgaris

et al. 2002

View full text Add to dashboard Cite

Background: Topical corticosteroids and calcipotriol have been used separately for many years to treat psoriasis. A new combination ointment has been formulated, which contains both calcipotriol and the corticosteroid betamethasone dipropionate. Objective: To compare the combination ointment with betamethasone dipropionate ointment, calcipotriol ointment and ointment vehicle in patients with psoriasis vulgaris. Methods: 1,603 patients were randomised to one of the 4 double-blind treatments used once daily for 4 weeks. Results: Themean percentage change in the PASI at the end of treatment was –71.3 (combination), –57.2 (betamethasone), –46.1 (calcipotriol) and –22.7 (vehicle). The mean difference of combination minus betamethasone was –14.2 (95% CI: –17.6 to –10.8, p < 0.001), of combination minus calcipotriol –25.3 (95% CI: –28.7 to –21.9, p < 0.001) and of combination minus vehicle –48.3 (95% CI: –53.2 to –43.4, p < 0.001). 6.0% of patients (combination) reported local adverse reactions compared to 4.9% (betamethasone), 11.4% (calcipotriol) and 13.6% (vehicle). Conclusion: Calcipotriol/betamethasone dipropionate combination ointment used once daily is well tolerated and more effective than either active constituent used alone.

show abstract

Section: Introductionmentioning

confidence: 99%

A New Calcipotriol/Betamethasone Dipropionate Formulation (Daivobet<sup>TM</sup>) Is an Effective Once-Daily Treatment for Psoriasis vulgaris

et al. 2002

View full text Add to dashboard Cite

show abstract

“…So far, available formulations did not facilitate simultaneous application of calcipotriol and corticosteroids due to the instability of calcipotriol ointment when combined with other agents [14]. A new two-compound product containing calcipotriol and betamethasone dipropionate (Daivobet/Dovobet ointment) offers a more rapid onset of action and better efficacy than either agent used in monotherapy [10, 15, 16].…”

Section: Discussionmentioning

confidence: 99%

Cost-Effectiveness of Once-Daily Treatment with Calcipotriol/Betamethasone Dipropionate Followed by Calcipotriol Alone Compared with Tacalcitol in the Treatment of Psoriasis vulgaris

Peeters

Ortonne

Sitbon³

et al. 2005

Dermatology

View full text Add to dashboard Cite

Background: Daivobet^® is a once-daily treatment of psoriasis vulgaris containing betamethasone dipropionate and calcipotriol in a new ointment vehicle. Objective: To assess the cost-effectiveness of once-daily treatment with Daivobet (4 weeks) followed by calcipotriol (4 weeks) compared to tacalcitol (8 weeks). Methods: Resource utilization was assessed within a double-blind 8-week clinical trial (all treatments for psoriasis, adverse events and concomitant dermatological medication), estimated from the French societal perspective. Results: Total direct medical costs for psoriasis were comparable (Daivobet: EUR 107.53 and tacalcitol EUR 113.50) despite a higher acquisition cost for Daivobet. The probability of ≧75% reduction in the Psoriasis Area and Severity Index (effectiveness criterion) was 46.6% with Daivobet and 13.9% with tacalcitol at 4 weeks, and 44.6 and 23.8%, respectively, at 8 weeks (both: p < 0.001). Over 8 weeks, Daivobet was almost twice as cost-effective as tacalcitol (EUR 241.22 per successful treatment vs. EUR 476.70); this result was robust to sensitivity assumptions. Conclusion: Daivobet is more effective and less costly than tacalcitol for treating psoriasis.

show abstract

“…Speci®cally, the molecule is destabilized and inactivated by an acidic environment. 13 Patel et al 14 evaluated the compatibility of calcipotriene with other topical therapies. The study demonstrated that hydrocortisone-17-valerate 0.2% ointment, 12% ammonium lactate lotion, and 6% salicylic acid result in degradation of calcipotriene.…”

Section: Calcipotriene and Corticosteroidsmentioning

confidence: 99%

“…The study demonstrated that hydrocortisone-17-valerate 0.2% ointment, 12% ammonium lactate lotion, and 6% salicylic acid result in degradation of calcipotriene. 13,14 Unlike hydrocortisone-17-valerate ointment, halobetasol propionate ointment and cream were compatible with calcipotriene for at least 13 days. 14 …”

Section: Calcipotriene and Corticosteroidsmentioning

confidence: 99%

See 1 more Smart Citation

Drug Interactions in Psoriasis: The Pros and Cons of Combining Topical Psoriasis Therapies

Endzweig-Gribetz¹,

Brady²,

Lynde³

et al. 2002

Journal of Cutaneous Medicine and Surgery: Incorporating Medica

Self Cite

View full text Add to dashboard Cite

Compatibility of calcipotriene with other topical medications

Cited by 91 publications

References 1 publication

A New Calcipotriol/Betamethasone Dipropionate Formulation (Daivobet<sup>TM</sup>) Is an Effective Once-Daily Treatment for Psoriasis vulgaris

A New Calcipotriol/Betamethasone Dipropionate Formulation (Daivobet<sup>TM</sup>) Is an Effective Once-Daily Treatment for Psoriasis vulgaris

Cost-Effectiveness of Once-Daily Treatment with Calcipotriol/Betamethasone Dipropionate Followed by Calcipotriol Alone Compared with Tacalcitol in the Treatment of Psoriasis vulgaris

Drug Interactions in Psoriasis: The Pros and Cons of Combining Topical Psoriasis Therapies

Contact Info

Product

Resources

About